Want to see PLRX full AI Analyst Report?
PLRX Stock Chart & Stats
$1.11
$0.00(0.00%)
At close: 4:00 PM EDT
$1.11
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.85 - $1.95
Previous CloseN/A
Volume89.08K
Average Volume (3M)397.77K
Market Cap
$56.50M
Enterprise Value-$58.77M
Total Cash (Recent Filing)$158.10M
Total Debt (Recent Filing)$28.74M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Nov 05, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding61,921,898
10 Day Avg. Volume483,433
30 Day Avg. Volume397,775
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-0.58
Enterprise Value/Market Cap-1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit222.61
Enterprise Value/Ebitda0.67
Forecast
1Y Price Target
$2.50Price Target Upside125.23% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-1.46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Narrowing LossesThe substantial reduction in net losses indicates improving cost discipline or a more focused development structure. While Pliant remains unprofitable, continued improvement could extend its financial runway and reduce the pace at which capital is consumed over the next several quarters.
Moderating Cash BurnLower cash usage is a constructive operational trend for a clinical-stage biotech because it can preserve funding for pipeline development and reduce near-term financing pressure. The improvement is meaningful even though cash generation remains negative and further progress is required.
Modest LeverageModest leverage gives Pliant more balance-sheet flexibility than a highly indebted development-stage company. With debt relatively low compared with equity, the company may have greater capacity to manage its development program without debt service becoming the primary constraint on operations.
Bears Say
No Commercial RevenueThe lack of a revenue base means Pliant currently depends on external capital and development progress rather than operating receipts to fund its business. This limits financial self-sufficiency and leaves future earnings highly dependent on successful clinical and commercial execution.
Persistent UnprofitabilityPliant continues to consume capital without generating profits, so earnings visibility remains weak over the medium term. Persistent losses can constrain strategic flexibility and make the company more dependent on favorable financing conditions or successful pipeline advancement to support ongoing operations.
Negative Cash GenerationOngoing negative operating and free cash flow indicates that the business still requires substantial funding to continue development. Combined with the long-term decline in equity, this trajectory raises the risk of additional financing needs and potential dilution if losses persist.
Pliant Therapeutics News
PLRX FAQ
What was Pliant Therapeutics’s price range in the past 12 months?
Pliant Therapeutics lowest stock price was $0.85 and its highest was $1.95 in the past 12 months.
What is Pliant Therapeutics’s market cap?
Pliant Therapeutics’s market cap is $56.50M.
When is Pliant Therapeutics’s upcoming earnings report date?
Pliant Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were Pliant Therapeutics’s earnings last quarter?
Pliant Therapeutics released its earnings results on Aug 11, 2026. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.342 by -$0.018.
Is Pliant Therapeutics overvalued?
According to Wall Street analysts Pliant Therapeutics’s price is currently Undervalued.
Does Pliant Therapeutics pay dividends?
Pliant Therapeutics does not currently pay dividends.
What is Pliant Therapeutics’s EPS estimate?
Pliant Therapeutics’s EPS estimate is -0.37.
How many shares outstanding does Pliant Therapeutics have?
Pliant Therapeutics has 61,921,898 shares outstanding.
What happened to Pliant Therapeutics’s price movement after its last earnings report?
Pliant Therapeutics reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.342. Following the earnings report the stock price went up 3.883%.
Which hedge fund is a major shareholder of Pliant Therapeutics?
Currently, no hedge funds are holding shares in PLRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pliant Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.50 (125.23% Upside)
$2.50 (125.23% Upside)
Hedge Fund Trend
Decreased
By 370.3K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.20%
12-Months-Change
Fundamentals
Return on Equity
-53.22%
Trailing 12-Months
Asset Growth
-36.67%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pliant Therapeutics
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
PLRX Stock 12 Month Forecast
Average Price Target
$2.50
▲(125.23% Upside)
Technical Analysis
aTyr Pharma
―
Rein Therapeutics
―
Gossamer Bio
―
Aligos Therapeutics
―
Fractyl Health, Inc.
―
Ownership Overview
2.48% Insiders
6.05% Mutual Funds
1.96% Other Institutional Investors
84.97% Public Companies and
Individual Investors